We have written about the promise of gene therapy to correct genetic disease many times. An exciting development happened ...

First company to enable precision in vivo genome engineering, combining both cell-specific delivery and programmable, locus-specific gene insertion, with the potential to achieve physiological, ...

A new West Coast biotech has emerged into the busy in vivo cell therapy space, this time with the backing of Nobel Prize-winning CRISPR pioneer Jennifer Doudna, Ph.D. Azalea Therapeutics has bloomed ...

Vertex Pharmaceuticals (VRTX) is rated as a "Strong Buy" due to robust revenue growth and multiple expansion opportunities ...

Recognized in the Biotechnology category of the 2025 Top Innovations contest, small Cas12l nucleases are versatile, ...

NEW YORK – Azalea Therapeutics launched on Tuesday, having raised $82 million in seed and Series A financing to develop in vivo genetic medicines for cancer and autoimmune conditions using its ...

Learn why research that continues to look for new substrate alternatives is essential to the future of growing.

Late last year, dozens of researchers spanning thousands of miles banded together in a race to save one baby boy’s life. The result was a world first: a cutting-edge, gene-editing therapy fashioned ...

PCSK9 inhibition may be a suitable alternative for statin-intolerant patients, and recent data demonstrated its efficacy as ...

Johns Hopkins University School of Medicine alumnus and former faculty member Hamilton O. Smith, M.D., whose 1978 Nobel Prize-winning discovery of restriction enzymes revolutionized genetic ...